Collegium Pharmaceutical develops and plans to commercialize abuse-deterrent medications using its patent-protected DETERx technology platform. Its lead product candidate is Xtampza ER (oxycodone extended-release capsules), for which the FDA accepted the New Drug Application in February 2015. The company intends to use the newly raised funds to advance Xtampza ER through potential FDA approval and a commercial launch. Collegium also plans to grow operations and advance other pipeline development programs. The company is led by CEO Michael Heffernan and focuses on treatments for chronic pain and other diseases. Collegium Pharmaceutical is a specialty pharmaceutical company in Cumberland, R.I., focused on developing treatments for chronic pain using its patent‑protected DETERx® drug delivery platform. The DETERx technology is a multi‑particulate matrix formulation in a capsule designed to provide extended‑release delivery and tamper‑resistant properties to protect against chewing, crushing, snorting and extraction for injection. The company’s lead product using the platform is COL-003, a tamper‑resistant, extended‑release oxycodone formulation. Collegium has initiated a Phase III trial for COL-003 and expects to file an NDA in 2013. The company states the platform also enables flexible dose administration (e.g., opening the capsule onto food or via a gastrostomy tube) and is covered by U.S. and international patents and applications. The Series B financing announced will support completion of development activities and the company through FDA approval of COL-003.

Total raised

$73M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2015